Apogee Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDApogee Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings contraction of 12% provides fundamental context to the price action. However, with RSI at 82, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $112.01 | +19.22% | ABOVE |
| 50 SMA | $94.37 | +41.50% | ABOVE |
| 100 SMA | $85.68 | +55.86% | ABOVE |
| 150 SMA | $81.91 | +63.03% | ABOVE |
| 200 SMA | $74.62 | +78.96% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is APGE in an uptrend right now?
APGE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, APGE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is APGE overbought or oversold?
APGE's RSI (14) is 82. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is APGE outperforming the market?
APGE has a Relative Strength (RS) Rating of 96 out of 99. Yes, APGE is a market leader, outperforming 96% of all stocks over the past 12 months.
Where is APGE in its 52-week range?
APGE is trading at $133.54, which is 100% of its 52-week high ($133.84) and 100% above its 52-week low ($34.34).
How volatile is APGE?
APGE has a Beta of 1.21 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.